[1] 马丽,刘冬梅,谢艳凤.比索洛尔对高血压伴心力衰竭合并慢性阻塞性肺疾病患者心肺功能的影响[J].河北医学,2017,23(6):1002-1005.
[2] 林祥兵,丁震.合并右心衰竭对慢性阻塞性肺疾病急性加重频率及严重程度的影响[J].内科急危重症杂志,2019,25(1):45-47.
[3] Goulart CDL, Dos Santos PB, Caruso FR, et al.The Value of Cardiopulmonary Exercise Testing in Determining Severity in Patients with both Systolic Heart Failure and COPD[J].Sci Rep. 2020;10(1):4309.
[4] 林文婷,曾敏,何扬利, 等.托拉塞米联合阿托伐他汀对COPD伴急性心力衰竭病人血清炎症因子、基质金属蛋白酶水平的影响[J].中西医结合心脑血管病杂志,2019,17(15):2316-2320.
[5] Arian A, Mortazavi Moghadam SG, Kazemi T, et al.Trial of Atorvastatin on Serum Interleukin-6, Total Antioxidant Capacity, C-Reactive Protein, and Alpha-1 Antitrypsin in Patients with Chronic Obstructive Pulmonary Disease[J].J Res Pharm Pract. 2018;7(3):141-146.
[6] 李文卉.阿托伐他汀对COPD稳定期患者气道重塑的影响[J].西南国防医药,2019,29(4):441-443.
[7] Buhr RG, Jackson NJ, Dubinett SM, et al.Factors Associated with Differential Readmission Diagnoses Following Acute Exacerbations of Chronic Obstructive Pulmonary Disease[J].J Hosp Med, 2020,15(2):e1-e9.
[8] 蒋宏辉,何华,赖春进.阿托伐他汀对COPD急性加重期患者肺功能及诱导痰VEGF水平的影响[J].海南医学,2018,29(14):1951-1953. |
